BRPI0821252A2 - Anticorpos ao vírus da hepatite c - Google Patents

Anticorpos ao vírus da hepatite c

Info

Publication number
BRPI0821252A2
BRPI0821252A2 BRPI0821252-0A BRPI0821252A BRPI0821252A2 BR PI0821252 A2 BRPI0821252 A2 BR PI0821252A2 BR PI0821252 A BRPI0821252 A BR PI0821252A BR PI0821252 A2 BRPI0821252 A2 BR PI0821252A2
Authority
BR
Brazil
Prior art keywords
hepatitis
virus antibodies
antibodies
virus
Prior art date
Application number
BRPI0821252-0A
Other languages
English (en)
Portuguese (pt)
Inventor
David J Matthews
David G Williams
Arvind Patel
Original Assignee
Medical Res Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council Technology filed Critical Medical Res Council Technology
Publication of BRPI0821252A2 publication Critical patent/BRPI0821252A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
BRPI0821252-0A 2007-12-17 2008-12-17 Anticorpos ao vírus da hepatite c BRPI0821252A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US606607P 2007-12-17 2007-12-17
PCT/IB2008/003952 WO2009081285A2 (en) 2007-12-17 2008-12-17 Hepatitis c virus antibodies

Publications (1)

Publication Number Publication Date
BRPI0821252A2 true BRPI0821252A2 (pt) 2015-06-16

Family

ID=40801628

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821252-0A BRPI0821252A2 (pt) 2007-12-17 2008-12-17 Anticorpos ao vírus da hepatite c

Country Status (18)

Country Link
US (1) US9193781B2 (enExample)
EP (1) EP2231704B1 (enExample)
JP (1) JP5763344B2 (enExample)
KR (1) KR20100102163A (enExample)
CN (1) CN101939334B (enExample)
AR (1) AR072039A1 (enExample)
AU (1) AU2008341542B2 (enExample)
BR (1) BRPI0821252A2 (enExample)
CA (1) CA2708740C (enExample)
CL (1) CL2008003784A1 (enExample)
IL (1) IL205795A0 (enExample)
MX (1) MX2010006767A (enExample)
NZ (1) NZ585622A (enExample)
PE (1) PE20091109A1 (enExample)
RU (1) RU2462475C2 (enExample)
TW (1) TW200940090A (enExample)
WO (1) WO2009081285A2 (enExample)
ZA (1) ZA201003509B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2348736T3 (es) 2004-10-07 2010-12-13 Transmedics, Inc. Sistemas yh metodos para cuidado de organos ex-vivo.
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US9814230B2 (en) 2008-01-31 2017-11-14 Transmedics, Inc. Systems and methods for ex vivo lung care
KR20110101212A (ko) * 2008-12-17 2011-09-15 제넨테크, 인크. Ｃ형 간염 바이러스 조합 요법
ES2913104T3 (es) 2011-04-14 2022-05-31 Transmedics Inc Solución de cuidado de órganos para perfusión en máquina ex-vivo de pulmones de donantes
EP2705150B1 (en) 2011-05-02 2020-07-29 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
WO2013033319A2 (en) * 2011-08-30 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University A cluster of neutralizing antibodies to hepatitis c virus
CN108759513A (zh) * 2011-12-09 2018-11-06 应用材料公司 用于冷却加热管的热交换器和所述冷却的方法
ITFI20120122A1 (it) * 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
CN102928595A (zh) * 2012-10-12 2013-02-13 武汉康苑生物医药科技有限公司 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
RU2685185C2 (ru) 2013-09-19 2019-04-16 Новавакс, Инк. Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
CN106659151B (zh) 2014-06-02 2021-06-08 特兰斯迈迪茨公司 离体器官护理系统
GB201415714D0 (en) 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CA3155169A1 (en) 2014-12-12 2016-06-16 Tevosol, Inc. Apparatus and method for organ perfusion
EP3824731B1 (en) 2015-09-09 2025-02-19 Transmedics, Inc. Aortic cannula for ex vivo organ care system
CN105219780B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用
CN105177017B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r4-85及其应用
WO2017162678A1 (en) * 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
EP3462861B9 (en) 2016-05-30 2023-12-20 Transmedics, Inc. Method for ex vivo lung ventilation with a varying exterior pressure
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022655A1 (en) * 1991-06-10 1992-12-23 Lucky Limited Hepatitis c diagnostics and vaccines
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
US20060188511A1 (en) 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
JP2004524829A (ja) 2000-12-01 2004-08-19 アメリカ合衆国 Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用
ITRM20020049A1 (it) * 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
JP2008532559A (ja) * 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善

Also Published As

Publication number Publication date
JP5763344B2 (ja) 2015-08-12
HK1144440A1 (en) 2011-02-18
WO2009081285A3 (en) 2010-08-26
KR20100102163A (ko) 2010-09-20
TW200940090A (en) 2009-10-01
WO2009081285A2 (en) 2009-07-02
RU2462475C2 (ru) 2012-09-27
AU2008341542A1 (en) 2009-07-02
US20110002926A1 (en) 2011-01-06
AU2008341542B2 (en) 2014-12-04
EP2231704A2 (en) 2010-09-29
CN101939334B (zh) 2015-01-14
NZ585622A (en) 2012-10-26
JP2011505867A (ja) 2011-03-03
RU2010129429A (ru) 2012-01-27
EP2231704B1 (en) 2015-08-12
CL2008003784A1 (es) 2009-08-14
CA2708740C (en) 2017-07-18
AR072039A1 (es) 2010-08-04
CA2708740A1 (en) 2009-07-02
CN101939334A (zh) 2011-01-05
ZA201003509B (en) 2011-12-28
IL205795A0 (en) 2010-11-30
PE20091109A1 (es) 2009-08-12
US9193781B2 (en) 2015-11-24
MX2010006767A (es) 2010-10-05

Similar Documents

Publication Publication Date Title
BRPI0821252A2 (pt) Anticorpos ao vírus da hepatite c
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0716483A2 (pt) inibidores do vírus da hepatite c
BRPI0908240A2 (pt) inibidores do vírus da hepatite c
BRPI0907733A2 (pt) Inibidores do vírus da hepatite c
DK3192874T3 (da) Virusoprensning
BRPI1010506A2 (pt) "inibidores do vírus da hepatite c"
EP2198016A4 (en) ADENO ASSOCIATED SWINE VIRUS
DK2049559T3 (da) Forbedrede HPV vacciner
HUE038501T2 (hu) Antitest készítmények
DK2066695T3 (da) Anti-myostatin-antistoffer
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI1007836A2 (pt) Inibidores do vírus c da hepatite
BRPI1008846A2 (pt) inibidores do vírus da hepatite c
BRPI1013393A2 (pt) inibidores do vírus da hepatite c
EP1983047A4 (en) Novel viral vector
IL194920A0 (en) Hepatitis c virus infection biomarkers
BRPI0716455A2 (pt) Desenvolvimento de componentes de vacina do vírus da dengue
EP2138375A4 (en) STROLLER
DE602008000498D1 (de) Kinderwagen
EP2138376A4 (en) STROLLER
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
BRPI0821034A2 (pt) Vírus influenza modificado
BRPI0909633A2 (pt) anticorpos anti-tyrp1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.